Tampere, Finland, May 15, 2025 / PRNewswire / -The Bioretec board has designated MBA Sarah van Hellenberg Hubar-Fisher as the company’s interim CEO. Van Hellenberg Hubar-Fisher will occupy its position immediately.
Van Hellenberg Hubar-Fisher will continue as a member of the company’s board of directors and as a member of the Board Audit Committee, in addition to its role as CEO. As a result of the appointment of Van Hellenberg Hubar-Fisher, the Board of Directors has decided to transfer the duties of the Board of Remuneration Committee to the Board of Directors until it is coming.
The Bioretec Board of Directors will continue with the process of recruiting a new CEO.
“The CEO Sarah Van Hellenberg Hubar-Fisher begins the new growth phase for Bioretec. She brings more than 23 years of experience in global health leaders Kustaa Poutiainen.
“I could not be more excited about the next growth phases for Bioretec and the opportunity to take us there. Biorete is ready to aim at market leadership, and our organization is ready to promote its realization for patients who deserve and have been waiting for high quality and reliable absorbable implants,” says Sarah Van Hellenberg Hub-Fisher.
Bioretec Ltd
Board of Directors
Other consultations
Kustaa Poutiaine, President of the Board, +358 40 042 4506
Certified advisor
Nordic Certified Advier Ab, +46 70 551 67 29
Bioretec shortly
Bioretec is a company of Finnish medical devices that operate worldwide that continues pioneer in the application of biodegradable orthopedic implants. The company has created unique skills in the biological interface of active implants to improve bone growth and accelerate the healing of fractures after orthopedic surgery. Developed and manufactured products by Bioretec are used worldwide in approximately 40 countries.
Bioretec is marketing and developing the new line of Remeos ™ products based on a magnesium alloy and a hybrid compound, a new generation of strong biodegradable materials for improved surgical results. REMENS ™ implants are absorbed and replaced by bone, which eliminates the need for extraction surgery while facilitating fracture healing. The combination has the potential to cause titanium implants to be redundant and help clinics achieve their medical care objectives based on value while focusing on patients through efficient medical care. The first authorization of the Remeos ™ product market has been received in the United States in March 2023, and in Europe, the approval of the CE brand was received in January 2025. Biorete is positioning to enter the orthopedic trauma and the global market of more than USD 9 billion orthopedic and the market of the spine bone
Better healing – Best Life. www.bioretec.com
This information was presented by Cision http://news.cision.com
https://news.cision.com/bioretec/r/inside-information-sarah-van-hellenberg-hubar-fisher-apoeded-interim-ceo-Ofo-of-bioretec.c4150768
